Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $46.47
  • 50 Day Moving Average: $46.770
  • 200 Day Moving Average: $49.870
  • 52-Week Range: $30.35 - $60.98
  • Trailing P/E Ratio: 5.451
  • Foreward P/E Ratio: -30.84
  • P/E Growth: 0.250
  • Market Cap: $1.32B
  • Outstanding Shares: 27,138,000
  • Beta: 4.36
Profitability:
  • Net Margins: 64.94%
  • Return on Equity: 59.23%
  • Return on Assets: 49.60%
Debt:
  • Current Ratio: 11.60%
  • Quick Ratio: 11.60%
Additional Links:
Companies Related to Five Prime Therapeutics:

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $55.83 (19.89% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetDetails
12/9/2016Jefferies Group LLCSet Price TargetBuy$60.00View Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00View Rating Details
10/25/2016Citigroup Inc.Initiated CoverageBuy$65.00View Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00View Rating Details
5/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$48.00View Rating Details
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00View Rating Details
12/4/2015Wells Fargo & CompanyReiterated RatingOutperformView Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$31.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.53)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.10)($0.55)$4.65 millionViewN/AView Earnings Details
11/10/2014($0.40)($0.33)ViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)ViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)ViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
Current Year EPS Consensus Estimate: $-3.15 EPS
Next Year EPS Consensus Estimate: $-1.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.87)($0.46)($0.62)
Q2 20162($0.76)($0.57)($0.67)
Q3 20163($0.80)($0.53)($0.65)
Q4 20163($1.38)($0.59)($0.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 93.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017William R RingoDirectorSell500$46.17$23,085.00View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.04View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.40View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.52View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.00View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
DateHeadline
finance.yahoo.com logoEdited Transcript of FPRX earnings conference call or presentation 23-Feb-17 9:30pm GMT (NASDAQ:FPRX)
finance.yahoo.com - February 24 at 11:12 AM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 10-K, Annual Report (NASDAQ:FPRX)
biz.yahoo.com - February 24 at 11:12 AM
seekingalpha.com logoFive Prime Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:FPRX)
seekingalpha.com - February 23 at 10:18 PM
us.rd.yahoo.com logo4:11 pm Five Prime Therapeutics misses by $0.18, beats on revs (NASDAQ:FPRX)
us.rd.yahoo.com - February 23 at 10:18 PM
sg.finance.yahoo.com logoFive Prime Therapeutics posts 4Q loss (NASDAQ:FPRX)
sg.finance.yahoo.com - February 23 at 10:18 PM
News IconSteering Attention Towards Earnings; Analysts Weigh in on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock - Aiken Advocate (NASDAQ:FPRX)
aikenadvocate.com - February 23 at 5:16 PM
News IconInvestor Radar: Taking a Closer Look at Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - The Standard (NASDAQ:FPRX)
6milestandard.com - February 23 at 5:16 PM
globenewswire.com logoFive Prime Announces Fourth Quarter and Full Year 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:FPRX)
globenewswire.com - February 23 at 5:16 PM
News IconLooking at the Gauges on Five Prime Therapeutics Inc (FPRX) - Baldwin Journal (NASDAQ:FPRX)
baldwinjournal.com - February 23 at 5:16 PM
biz.yahoo.com logoQ4 2016 Five Prime Therapeutics Inc Earnings Release - After Market Close (NASDAQ:FPRX)
biz.yahoo.com - February 23 at 5:16 PM
finance.yahoo.com logoFive Prime Announces Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:FPRX)
finance.yahoo.com - February 23 at 5:16 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:FPRX)
biz.yahoo.com - February 23 at 5:16 PM
investornewswire.com logoStrong Sell Recommendations Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) At 0 - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - February 20 at 4:51 PM
News IconFive Prime Therapeutics Inc FPRX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:FPRX)
www.bioportfolio.com - February 18 at 12:12 PM
4-traders.com logoFIVE PRIME THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:FPRX)
www.4-traders.com - February 13 at 6:06 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:FPRX)
biz.yahoo.com - February 13 at 6:06 PM
nasdaq.com logoFive Prime Therapeutics to Announce Fourth Quarter and Full Year ... - Nasdaq (NASDAQ:FPRX)
www.nasdaq.com - February 10 at 3:58 AM
streetinsider.com logoForm 4 FIVE PRIME THERAPEUTICS For: Feb 07 Filed by: Baker Kevin Paul (NASDAQ:FPRX)
www.streetinsider.com - February 9 at 10:56 PM
finance.yahoo.com logoFive Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23 (NASDAQ:FPRX)
finance.yahoo.com - February 9 at 5:55 PM
finance.yahoo.com logoFive Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting (NASDAQ:FPRX)
finance.yahoo.com - February 8 at 5:51 PM
finance.yahoo.com logoFive Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:FPRX)
finance.yahoo.com - February 8 at 5:51 PM
News IconDirector of Five Prime Therapeutics (NASDAQ:FPRX), Ringo William R, sells 500 shares worth $23,085 (NASDAQ:FPRX)
empowerednews.net - February 1 at 10:59 PM
nasdaq.com logoCommit To Buy Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options (NASDAQ:FPRX)
www.nasdaq.com - February 1 at 5:57 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)? - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 31 at 5:58 PM
News IconValue Composite Score Update on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - The Tribune (NASDAQ:FPRX)
lakecitytribune.com - January 29 at 3:31 AM
News IconWatching the Charts on Five Prime Therapeutics Inc. (FPRX) - Springdale Times (NASDAQ:FPRX)
springdaletimes.com - January 29 at 3:31 AM
News IconTrading Lines in Focus for Five Prime Therapeutics Inc. (FPRX) - Springdale Times (NASDAQ:FPRX)
springdaletimes.com - January 27 at 7:01 PM
insidermonkey.com logoCabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation - Insider Monkey (blog) (NASDAQ:FPRX)
www.insidermonkey.com - January 25 at 11:56 PM
News IconCabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation (NASDAQ:FPRX)
feedproxy.google.com - January 25 at 11:01 AM
reuters.com logoBRIEF-Five Prime Therapeutics gets orphan drug designation from European Commission for cabiralizumab (NASDAQ:FPRX)
www.reuters.com - January 25 at 5:09 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces EC Orphan Drug Designation for Cabiralizumab (FPA008) for PVNS (NASDAQ:FPRX)
www.streetinsider.com - January 25 at 5:09 AM
News IconFocusing on the Charts for Five Prime Therapeutics Inc. (FPRX) - Springdale Times (NASDAQ:FPRX)
springdaletimes.com - January 24 at 5:57 PM
News IconEarnings in Full Force, Analysts Take Aim at Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 24 at 5:57 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces EC Orphan Drug Designation for Cabiralizumab (FPA008) for PVNS - StreetInsider.com (NASDAQ:FPRX)
www.streetinsider.com - January 24 at 5:57 PM
finance.yahoo.com logoEuropean Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS) (NASDAQ:FPRX)
finance.yahoo.com - January 24 at 5:57 PM
News IconThe Brokerages Set Cidara Therapeutics Inc. (CDTX) PT at $19.21 (NASDAQ:FPRX)
diariocatolico.net - January 22 at 5:06 PM
streetinsider.com logoForm 4 FIVE PRIME THERAPEUTICS For: Jan 18 Filed by: Sarena Francis Willard (NASDAQ:FPRX)
www.streetinsider.com - January 20 at 12:00 AM
News IconDownward Trend Continues as Stock Can't Find Its Footing: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 19 at 3:55 AM
News IconShares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Sees Large Inflow of Net Money Flow - Highland Mirror (NASDAQ:FPRX)
www.highlandmirror.com - January 19 at 3:55 AM
News IconWhat are the Technical Charts Saying About Five Prime Therapeutics Inc. (FPRX) - Springdale Times (NASDAQ:FPRX)
springdaletimes.com - January 17 at 7:29 AM
News IconWill The Needle Move For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 17 at 7:29 AM
News IconFive Prime Therapeutics Inc FPRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:FPRX)
www.bioportfolio.com - January 13 at 6:13 PM
News IconTrading Corner: Eye on Technical Levels for Five Prime Therapeutics Inc. (FPRX) - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 12 at 5:44 PM
News IconStock Getting Tripped Up In Session: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Beacon (NASDAQ:FPRX)
wsbeacon.com - January 11 at 5:53 PM
marketexclusive.com logoFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Results of Operations and Financial Condition (NASDAQ:FPRX)
marketexclusive.com - January 9 at 6:06 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu (NASDAQ:FPRX)
biz.yahoo.com - January 9 at 6:06 PM
marketexclusive.com logoBristol-Myers Squibb Co (NYSE:BMY) Agrees To Extend Research With Five Prime Therapeutics Inc (NASDAQ:FPRX) (NASDAQ:FPRX)
marketexclusive.com - January 5 at 11:13 PM
News IconBristol-Myers Squibb Co (BMY) Agrees To Extend Research With Five Prime Therapeutics Inc (FPRX) (NASDAQ:FPRX)
feedproxy.google.com - January 5 at 11:37 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Says Bristol-Myers Squibb (BMY) Exercised Option to Extend Collaboration - StreetInsider.com (NASDAQ:FPRX)
www.streetinsider.com - January 4 at 11:24 PM
seekingalpha.com logoBristol-Myers re-ups with Five Prime in immuno-oncology (NASDAQ:FPRX)
seekingalpha.com - January 4 at 6:24 PM

Social

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?

6 analysts have issued twelve-month price targets for Five Prime Therapeutics' shares. Their predictions range from $48.00 to $65.00. On average, they anticipate Five Prime Therapeutics' share price to reach $55.83 in the next year.

When will Five Prime Therapeutics announce their earnings?

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Five Prime Therapeutics stock?

Five Prime Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.72%), State Street Corp (3.66%), Dimensional Fund Advisors LP (3.10%), Eventide Asset Management LLC (2.98%), EcoR1 Capital LLC (1.10%) and Russell Investments Group Ltd. (0.69%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo.

Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Deerfield Management Co., State Street Corp, AQR Capital Management LLC, Pacad Investment Ltd., Guggenheim Capital LLC, State Board of Administration of Florida Retirement System and Tudor Investment Corp Et Al. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo.

Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Perceptive Advisors LLC, Dimensional Fund Advisors LP, Advisory Research Inc., Oxford Asset Management, Numeric Investors LLC, FMR LLC and United Capital Financial Advisers LLC.

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Five Prime Therapeutics stock cost?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $46.57.

Five Prime Therapeutics (NASDAQ:FPRX) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Earnings History Chart

Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Dividend History Chart

Dividend Payments by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Last Updated on 2/24/2017 by MarketBeat.com Staff